ClinicalTrials.gg
RecruitingNCT07684170Updated Nov 9, 2026

Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms

A Phase 2 interventional study of CTX-471 in Neuroendocrine Neoplasm, Neuroendocrine Carcinomas and Neuroendocrine Tumors, sponsored by Compass Therapeutics. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Primary conditionCarcinoma, NeuroendocrineRegistry: Neuroendocrine TumorsReclassifiedWhy we changed it
Registry
Neuroendocrine Tumors — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Neuroendocrine
Why
  1. The study's listed conditions name Carcinoma, Neuroendocrine, a narrower term within Neuroendocrine Tumors.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Compass Therapeutics · Phase 2, Interventional, and Treatment

Updated Nov 9, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 73 studies in Carcinoma, Neuroendocrine with a site in United States — 19 open to participants now, 32 under way, 1 of them phase 3. Carcinoma, Neuroendocrine · United States.

Planned enrollment
34th of 65
58 · median 60
Started
2026
with 6 others
Phase 2
30 of 73
2 open now
Primary completion
2028-09
later than 23 of 31 live
Registered
72nd of 73
by date

Among the 73 studies in Carcinoma, Neuroendocrine with a site in United States, this one is the 34th largest by planned enrollment of the 65 interventional ones that give a count, is one of 7 that started in 2026, is one of 30 in phase 2, reaches primary completion later than 23 of the 31 other live ones, and was the 72nd registered.

Carcinoma, Neuroendocrine

172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 66 are open to participants now.

Browse Carcinoma, Neuroendocrine studies →

Open to participants now

19 of the 73 studies in Carcinoma, Neuroendocrine with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Carcinoma, Neuroendocrine studies recruiting now, 30 (64%) set no upper age limit and 10 (21%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Carcinoma, Neuroendocrine with a site in United States, or all of them as a file.
02

Study summary

This study will enroll patients with central lab confirmed NCAM (CD56 IHC) positive metastatic neuroendocrine neoplasms that have progressed after standard of care treatment. CTX-471 to be administered as an intravenous (IV) infusion at either 0.3 mg/kg or 0.6 mg/kg every 2 weeks until disease progression or unacceptable toxicity. The study will be conducted in two stages. In Stage 1, 18 patients will be accrued for each dose level. If there are less than 2 objective responses in these 18 patients at either dose level, the dose level will be stopped. Otherwise, an additional 22 patients will be accrued in Stage 2 with 11 patients for each dose level.

03

Conditions studied

  • Neuroendocrine Neoplasm
  • Neuroendocrine Carcinomas
  • Neuroendocrine Tumors

Browse trials for

04

In context

Carcinoma, Neuroendocrine Reclassified

172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 66 are open to participants now.

This study's planned enrollment of 58 is close to the median of 60 across 144 interventional studies indexed under Carcinoma, Neuroendocrine.

Browse Carcinoma, Neuroendocrine studies →

Lead sponsor

Compass Therapeutics is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Compared within Carcinoma, Neuroendocrine, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neuroendocrine Tumors. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older.
  2. Positive immunohistochemical staining for NCAM (defined as ≥ 1% of malignant cells with membranous/cytoplasmic staining of any intensity) on an archived (≤ 3 months) or freshly taken specimen (centrally tested) with confirmed diagnosis of tumors.
  3. Locally advanced unresectable or metastatic neuroendocrine neoplasm (NEN) defined by World Health Organization (WHO) (Rindi et al 2022) Grade 3 neuroendocrine tumor (NET) or neuroendocrine carcinoma (NEC) (Ki-67 > 20% and/or > 20 mitoses/10 hpf) and confirmed by histopathology or cytology (eg, gastroentero-pancreatic NECs (GEP-NEC) and lung NEC, other rare sites of origin such as genitourinary, gynecological, larynx, thyroid, or unknown origin).
  4. Patients must have received at least one and must have exhausted any other standard-of-care treatment option.

    a. Patients with histologically confirmed prostate NEC are not required to have received prior androgen deprivation therapy (ADT) or castrated levels of testosterone.

  5. A of 4 weeks or at least 5-fold half-life of the last dose (whichever is shorter) of prior systemic therapy prior to receiving the first dose of CTX-471.

    • The eligibility of patients who received unapproved drugs will be determined by discussion with the Sponsor Medical Monitor.
  6. (ECOG) performance status of 0-1.
  7. At least one definable by MRI or CT scan per version 1.1 criteria.
  8. All toxicities related to previous anti-cancer therapies have resolved to () Grade 1 prior to trial treatment administration (except for alopecia, peripheral neuropathy, fatigue and endocrinopathies controlled by replacement therapy which must be CTCAE Grade 2 and amenorrhea/menstrual disorders which can be any grade).
  9. Adequate organ function and laboratory values:

    • Adequate bone marrow function defined by absolute neutrophil (ANC) of ≥ 1.5×109/L, count of ≥ 100.0×109/L, and of ≥ 9.0 g/dL (with or without transfusion).
    • Adequate hepatic function defined as serum total ≤ 1.5 × , /ALT ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases or ≤3 x ULN for patients with Gilbert's syndrome).
    • Adequate renal function defined as ≥ 30 mL/min by Cockcroft-Gault equation.
  10. Females of (FOCBP) should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication.
  11. FOCBP must agree to use adequate as outlined in study documentation, starting with the first dose of study medication through 120 days after the last dose of study medication.
  12. Male patients of childbearing potential must agree to use an adequate method of contraception as outlined in study documentation, starting with the first dose of study medication through 120 days after the last dose of study medication.
  13. Capable of understanding and complying with protocol requirements.
  14. Signed and dated institutional review board (IRB) approved form (ICF) before any protocol-directed screening procedures are performed.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of well differentiated G1/G2 neuroendocrine neoplasm.
  2. Prior history of interstitial lung disease.
  3. Prior treatment of CD137 targeted therapy ( and approved).
  4. Symptomatic or uncontrolled central nervous system and or active . Patients with equivocal findings or with confirmed brain metastases are eligible for the study provided that they are asymptomatic and radiologically and neurologically stable without the need for treatment or seizure prophylaxis for ≥4 weeks before the first dose of study drug. Prior treatment with either surgery or radiation is permitted and all patients with a history of central nervous system (CNS) or brain lesions require imaging during screening to confirm stability.
  5. Prior solid organ transplantation and/ or an allogeneic tissue transplant.
  6. Active virus (HBV), virus (HCV) or (HIV) infection or a positive serological test at Screening within 35 days of dosing with CTX-471.

    • Hepatitis B surface antigen (HBsAg) positive patients are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization.
    • HBV+ patients should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention.
    • History of HCV infection is eligible if HCV viral load is undetectable at screening.
    • HCV+ patients must have completed curative anti-viral therapy at least 4 weeks prior to randomization.
  7. HIV-infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease defined as:

    • Patients on ART must have a \< 350 cells/mm3 at time of screening.
    • Patients on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 copies/mL or the lower limit of qualification (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks prior to screening.
    • Patients on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks prior to study entry (Day 1).
  8. Active disease or medical conditions requiring chronic steroid (ie, > 10 mg/day prednisone or equivalent) or therapy. Patients with a prior history of autoimmune disease may be eligible following discussion with the Medical Monitor.
  9. Systemic therapy with immunosuppressive agents within 7 days before the start of CTX-471 treatment. Topical, intranasal, intraocular, or inhaled corticosteroids and physiologic replacement for patients with adrenal insufficiency are allowed (≤ 10 mg/day prednisone or equivalent).
  10. Congestive heart failure (> Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias.
  11. Other systemic conditions or organ abnormalities that in the opinion of the Investigator may interfere with the conduct and/or interpretation of the current study.
  12. Has received prior radiotherapy within 2 weeks of start of study treatment.

    • Patients must have recovered from all radiation-related toxicities and not require corticosteroids.
  13. Has received a live or within 30 days prior to the first dose of study medication.

    • Administration of killed vaccines are allowed.
  14. Has a known additional that is progressing or has required active treatment within the past 3 years.

    • Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of bladder, that have undergone potentially curative therapy are not excluded.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Dose Level 0.3 mg/kg

    Drug: CTX-471

  • Experimental
    Dose Level 0.6 mg/kg

    Drug: CTX-471

Interventions

  • DrugCTX-471

    Patients will receive CTX-471 as an intravenous (IV) infusion every 2 weeks until disease progression or unacceptable toxicity.

07

What researchers measure

Primary outcomes

  1. Evaluate the clinical activity of CTX-471

    Objective Response Rate (ORR) (Percentage of Participants With Objective Response) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    Time frame: Baseline until confirmed disease progression (up to 1 year)

  2. Evaluate the safety of CTX-471

    Incidence of treatment emergent adverse events (TEAEs), treatment-related AEs (TREAEs), and serious adverse events (SAEs)

    Time frame: From first dose of CTX-471 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-471

  3. Determine the recommended phase 2 dose (RP2D) for CTX-471

    Efficacy, exposure, safety events, and markers of response will be aggregated to select a Phase 2 dose

    Time frame: From first dose of CTX-471 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-471

Secondary outcomes

  1. Duration of Response (DOR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    Time frame: From the date of first confirmed PR or CR until date of progression or death, whichever occurs first (up to 1 year)

  2. Disease Control Rate (DCR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    Time frame: From first dose of CTX-471 (Cycle 1 Day 1,Cycle = 2 weeks) until until disease progression or death, whichever occurs first (up to 1 year)

  3. Progression-Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    Time frame: From first dose of CTX-471(Cycle 1 Day 1,Cycle = 2 weeks ) until disease progression or death, whichever occurs first (up to 1 year)

  4. Median Progression-Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors(RECIST) Version 1.1

    Time frame: From first dose of CTX-471(Cycle 1 Day 1, Cycle = 2weeks ) until date of progression or death, whichever occurs first, for 50% of the study population, including time intervals of at 6 months and 12 months.

  5. Median Overall Survival (OS)

    Time frame: From first dose of CTX-471 (Cycle 1 Day 1,Cycle = 2weeks) until death for 50% of the study population, including time intervals at 6 months and 12 months.

  6. Maximum serum concentration (Cmax) of CTX-471

    Time frame: From first dose of CTX-471 (Cycle 1 Day 1,Cycle = 2 weeks) until treatment discontinuation (up to 1 year)

  7. Time of maximum observed serum concentration (Tmax) of CTX-471

    Time frame: From first dose of CTX-471 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation (up to 1 year)

  8. Trough serum concentration (Ctrough) of CTX-471

    Time frame: From first dose of CTX-471 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation (up to 1 year)

  9. Area under the serum concentrations of CTX-471 versus time curve (AUC) for CTX-471

    Time frame: From first dose of CTX-471 (Cycle 1 Day 1,Cycle = 2 weeks) until treatment discontinuation (up to 1 year)

  10. Clearance (CL) of serum concentrations of CTX-471

    Time frame: From first dose of CTX-471 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation (up to 1 year)

  11. Volume of distribution (Vd) of serum concentrations of CTX-471

    Time frame: From first dose of CTX-471 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation (up to 1 year)

  12. Half-life (t1/2) of serum concentrations of CTX-471

    Time frame: From first dose of CTX-471 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation (up to 1 year)

  13. Assess the immunogenicity of CTX-471

    Screen for the presence and development of antibodies against CTX-471

    Time frame: From first dose of CTX-471 (Cycle 1 Day 1, Cycle = 2 weeks) until end of treatment visit (up to 1 year)

08

Study locations

2 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Sep 2028, 22 months later.

Of 43 phase 2 interventional studies under Carcinoma, Neuroendocrine, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 91. This study's planned 22 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jul 6, 2026
StartEst.
Nov 2026was Sep 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
2 sites added — first site in United States
Show 2 added (2 United States)
  • Siteman Cancer Center · St Louis, United States
  • Fred Hutchinson Cancer Center · Seattle, United States
Nov 9, 2026
Start date
Sep 2026→Nov 2026
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in United States
    Show 2 added (2 United States)
    • Siteman Cancer Center · St Louis, United States
    • Fred Hutchinson Cancer Center · Seattle, United States
    Start date Sep 2026→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07684170
Lead sponsor
Compass Therapeutics
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Nov 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Compass Study Email
Contact
CTX-471-002@compasstherapeutics.com
617-500-8099

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion